GSK is a global biopharma company with the ambition and purpose to unite science, technology and talent to get ahead of disease together.
We aim to positively impact the health of 2.5 billion people over the next 10 years. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance.
We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.
Currently, we invest around £1bn in research and development (R&D) in the UK annually with our global R&D hub at Stevenage continuing to be at the heart of the development of our pipeline of vital medicines, with a focus on the immune system, genetics, and advanced technologies.
Our culture powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive. We are recognised in the Stonewall LGBT+ rights group as a top global employer and ranked in the Times Top 50 employers for women in the UK.
We also support our global and local communities. £1.7m has been raised by UK employees for Save the Children so far, with 100% of these funds being used to help provide UK families living on low incomes with essential household items, learning resources, and support that gives parents the skills, confidence and tools to help their children thrive.
Members of the public in the UK can obtain information about our products and areas of therapy by visiting our
Our locations in the UK
Contact details
GSK House
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
UK Corporate
Tel: +44 (0)20 8047 5000
UK Commercial
Tel: +44 (0)20 8990 9000
Back to top
Prescription medicines/customer support team
Email: customercontactuk@gsk.com
UK medical and safety information
Tel: 0800 221 441
Back to top
For general media enquiries visit Global media contacts
Back to top
We routinely monitor the safety of all our medicines and all adverse events should be reported to us and the Medicines and Healthcare products Regulatory Agency via their yellow card scheme. To report an adverse event, use our online Patient safety reporting form or email: uksafety@gsk.com or tel: 0800 221 441
Back to top
Use the UK HR main number to contact the right team for information regarding benefits and employment related questions:
Email: UKIRL.ServiceHR@gsk.com
Tel: +44 (0)20 7660 6942
Back to top
Careers
We’re working hard to become a more inclusive company through our recruitment and selection processes. To support you in your recruitment journey we have prepared answers to your frequently asked questions about how we hire for direct entry UK roles at GSK.
- UK Recruitment FAQ (PDF - 1.1MB)
- Apprenticeships GSK United Kingdom - apprenticeships
- Undergraduates GSK United Kingdom - undergraduates
- Graduates GSK United Kingdom - graduates
Healthcare professionals
Healthcare professionals (HCPs) in the UK can get information about our products and therapy areas by visiting GSKPro
As a healthcare company we regularly work with HCPs. From collaborating on clinical trials to providing high quality, balanced information about our medicines and vaccines, in all of our interactions we aim to be transparent about our work, operate with integrity, and always put the interests of patients first.
In line with EFPIA Disclosure Code, disclosure information in the UK is published annually (covering the previous year) through the Association of the British Pharmaceutical Industry (ABPI) Disclosure UK website. You can find more information on our disclosure of payments here.
Back to top
UK patients, journalists and members of public
In line with ABPI Code, we disclose payments for certain contracted services made to UK patients, journalists and members of the public, on an aggregate basis.
- 2022 Disclosure For Member Of Public Patients Journalists (PDF - 78.2KB)
- 2022 EFPIA HCPO Methodological Note English (PDF - 192.9KB)
Partnerships
Despite having some of the best people and research facilities, experience has shown us that we can achieve even more through strong partnerships.
These can be with the NHS, other companies, non-profit organisations and the academic world. In fact, it’s a key element in our business strategy, which helps us develop innovative new medicines and vaccines but also helps improve access to treatments and patient care
GSK Severe Asthma Patient Review Service Service Notification (PDF - 107.6KB)
Back to top
Joint working
We are actively involved in a wide number of joint working projects with the NHS throughout the UK. By working together we aim to improve the management of different conditions, introduce greater efficiency introduce greater efficiency and to achieve our ambition to unite science, technology and talent to get ahead of disease together.
The projects outlined below were undertaken over the last five years and, over this period, codes, regulations and laws governing the areas covered by the studies may have changed. When reading the documents please be assured that all projects followed the particular standards in force at the time even though these may have subsequently changed.
All of the featured case studies are intended to give an overview of the individual project including its background, the potential benefits for the patient, the NHS, GSK and any other stakeholders.
- Health Innovation Manchester and GSK Joint Working: Optimisation of care for people living with COPD in Greater Manchester (PDF - 114.4KB)
- Connected Inhaler Service Evaluation Project In The Routine Clinical Assessment Of Severe Asthma (PDF - 180.6KB)
- GlaxoSmithKline (UK Ltd) and Our Health Partnership COPD Project (PDF - 89.5KB)
- GlaxoSmithKline (UK Ltd) and Hampshire and Isle of Wight Integrated Care System (NHS Hampshire, Southampton and Isle of Wight Clinical Commissioning Group) COPD Project Joint Working Project (PDF - 132.0KB)
- NHS Greater Glasgow and Clyde Health Board and GSK Joint Working project- ‘Care Optimisation in Greater Glasgow and Clyde’ (PDF - 130.3KB)
- ICSJW 2024 Birmingham and Solihull Executive Summary (PDF - 151.2KB)
- Bedfordshire, Luton And Milton Keynes ICB And GSK Joint Working. Optimising COPD Care Across Bedfordshire, Luton And Milton Keynes (PDF - 115.8KB)
- GlaxoSmithKline (UK Ltd) and NHS Buckinghamshire, Oxfordshire and Berkshire West ICB Executive Summary (PDF - 147.0KB)
- Executive Summary UNITE Service Hampshire And Isle Of Wight ICS (PDF - 162.3KB)
- Executive Summary GSK Bury GP Federation Collaborative Working Shingles NIP Improvement (PDF - 94.5KB)
- Legacy COPD Project Across Black Country (PDF - 115.4KB)
- COPD Legacy Project Across Norfolk And Waveney (PDF - 121.7KB)
- East Kent Confed ICSJW Executive Summary (PDF - 119.2KB)
- GlaxoSmithKline (UK Ltd) and NHS Devon ICB COPD Joint Working Project Executive Summary (PDF - 172.6KB)
- Executive Summary GSK and Operose Health Collaborative Working Shingles NIP Quality Improvement Programme (PDF - 72.1KB)
Back to top
- Frimley Health Foundation Trust Joint Working 2019-2020 Summary of project (PDF - 118.8KB)
- Community Pharmacy Patient Inhaler Review Service Joint Working Aneurin Bevan Hywel Dda and Powys Summary of Outcomes (PDF - 88.1KB)
- Health Innovation Manchester Joint Working summary of project (PDF - 85.4KB)
- Summary of COPD risk stratification: Helping you to prioritise patients most in need Joint Working Project (GlaxoSmithKline (UK Ltd) and Frimley Health and Care Integrated Care System) 2021 – 2022 (PDF - 124.7KB)
- Bury GP Federation Collaborative Working Shingles NIP Outcomes Summary. (PDF - 261.2KB)
- Outcomes from the UNITE Service - Hull University Teaching Hospitals NHS Trust and GlaxoSmithKline UK Ltd (GSK) (PDF - 223.3KB)
- Summary of Outcomes of “Care optimisation in COPD service” Joint Working Project (GlaxoSmithKline (UK Ltd) and NHS Scottish Borders (PDF - 358.3KB)
Back to top
Back to top
Grants and donations
We recognise a responsibility to support activities in our medical community, whether related to medical education where there is patient need and common scientific interest, professional societies’ initiatives, or assisting healthcare organisations and projects that promote other healthcare goals. In all of our interactions we aim to be transparent about our work, operate with integrity, and always put the interests of patients first.
GSK UK’s Grants and Donations Committee uses the following criteria when assessing applications from Healthcare Organisations and Patient Advocacy Groups:
- The grant or donation must be used for an activity with a valid and legitimate purpose that enhances patient care, or benefits the NHS and maintains patient care. Programmes currently within scope for approval include:
- Patient Advocacy Group initiated Programmes and Core Funding
- Grants to organisations that support healthcare professionals and related staff to attend Scientific Congresses with decision-making independent of GSK
- Public policy and advocacy programs and initiatives, including legal reform and government relations
- The activity must be in a GSK disease area of strategic priority: Respiratory, Oncology, Specialty and COVID-19, Vaccines.
- Funding must be proportional to the activity and not excessive.
- Applications must be from a legitimate, reputable organisation that has the capability and licences to conduct the activity.
- The grant must be made in a manner that does not affect the independence of the recipient.
- A grant will only extend beyond one year under exceptional circ*mstances.
- A grant will not be given to an individual or be used for personal use.
- A grant cannot provide more than 25% of total funding received by a single recipient through GSK grants, except for rare disease or start-up patient groups, which can receive up to 50% of the total funding. Any exception requires additional approval and shall not exceed 50% in any case.
Please return your completedrequest formtogsk.grant-request@gsk.com. We will review qualifying grant requests and may reach out for additional information.
Carbon reduction plan
In accordance with UK Cabinet Office standards, the attachment below is GSK’s Carbon Reduction Plan completed in accordance with PPN 06/21 and associated guidance and reporting standards for Carbon Reduction Plans.
- GSK Carbon reduction plan March 2023 (PDF - 626.9KB)
- GSK Carbon reduction plan March 2024 (PDF - 371.0KB)
We have many opportunities for professionals interested in flexible contingent projects with GSK.
Please click here to register in the UK talent pool and access some of the most cutting-edge and exciting project opportunities. GSK’s Contractor & Agency Worker community and all associated activities are managed by our recruitment partner, TAPFIN, a ManpowerGroup Business
To learn more about our early talent programmes, visit our global Early Talent portal.Forearly talent programmes in the UK, please explore the pages below.
Back to top
STEM
We believe that science, technology, engineering and mathematics can change the world for the better. We want to show young people the impact they can have on the world around them through our education programme. Find our more
